Tarsus Pharmaceuticals develops and sells eye care treatments, including XDEMVY for an eyelid condition caused by mites. It last closed at $78.20 on Nov 17, down 0.61% on the day. TARS last reported earnings on Tue, Nov 3, 2026. The average 12-month price target from 5 analysts is $106.80 (+36.6% from the last close), with a high of $116.00 and a low of $97.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Each firm's latest rating on TARS in the past 90 days
Average 12-month target
$106.80
▲ 36.6% upside
Based on 5 analysts who set a price target on TARS in the past 90 days. The average target is $106.80, with a high of $116.00 and a low of $97.00, compared with the last close of $78.20.
Low $97.00Avg $106.80High $116.00
Blue marker: last close $78.20
Highest target$116.00
Average target$106.80
Lowest target$97.00
Latest rating changes
GuggenheimMaintained
Nov 5Buy$97
HC Wainwright & Co.Maintained
Nov 4Buy$106
Goldman SachsReinstated
Sep 24Buy$116
BarclaysReinstated
Sep 16Buy$110
JefferiesMaintained
Sep 8Buy$105
Date
Firm
Action
Rating
Price target
Nov 5
Guggenheim
Maintained
Buy
$97
Nov 4
HC Wainwright & Co.
Maintained
Buy
$106
Sep 24
Goldman Sachs
Reinstated
Buy
$116
Sep 16
Barclays
Reinstated
Buy
$110
Sep 8
Jefferies
Maintained
Buy
$105
Loading…
Technical Analysis
TARS · as of the Nov 17 close · updated after every close
Uptrend
The stock is 7% above its 20 day and 5% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot at $77.63, and the nearest resistance the Pivot R1 at $78.96.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 4.7%/day
Key levels
$91.5352 week high+17.0%
$79.10Swing high (Oct 1)+1.2%
$78.96Pivot R1+1.0%
$78.20Last close
$77.63Pivot−0.7%
$76.86Pivot S1−1.7%
$74.4250 day average−4.8%
$73.85Swing low (Sep 25)−5.6%
$72.9620 day average−6.7%
$70.44100 day average−9.9%
$68.10200 day average−12.9%
$53.8952 week low−31.1%
Indicators
RSI (14)
59.56
Middle of its range
Neutral
MACD
1.32
Above its signal line
Bullish
Stochastic
85.9
Near the top of its range
Overbought
ADX (14)
17.8
No clear trend
Williams %R
-19.9
Oversold below −80, overbought above −20
Overbought
CCI (20)
110.7
Oversold below −100, overbought above 100
Overbought
Rate of change
+7.7%
Change over 10 sessions
Bullish
ATR (14)
$3.68
Typical daily range, 4.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNormal
VolatilityNormal, 9.9%/day
Key levels
$91.5352 week high+17.0%
$79.10Swing high (Oct 1)+1.2%
$78.96Pivot R1+1.0%
$78.20Last close
$77.63Pivot−0.7%
$76.86Pivot S1−1.7%
$74.4250 day average−4.8%
$73.85Swing low (Sep 25)−5.6%
$72.9620 day average−6.7%
$70.44100 day average−9.9%
$68.10200 day average−12.9%
$53.8952 week low−31.1%
Indicators
RSI (14)
56.40
Middle of its range
Neutral
MACD
2.53
Above its signal line
Bullish
Stochastic
47.3
Middle of its range
Neutral
ADX (14)
23.3
Weak trend
Williams %R
-51.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
84.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.4%
Change over 10 sessions
Bearish
ATR (14)
$7.76
Typical daily range, 9.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for TARS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TARS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow TARS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TARS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TARS is in one of them and how their past TARS trades turned out.
Tarsus Pharmaceuticals is a biopharmaceutical company based in Irvine, California, focused on developing and selling treatments for eye care. Its main product, XDEMVY, is an eye solution approved in the United States for Demodex blepharitis, an inflammation of the eyelids caused by mites. The company markets this product to eye care professionals and is developing other treatments, including candidates for ocular rosacea and for preventing Lyme disease.